Literature DB >> 18634527

[SAPHO syndrome--clinical features].

Hanna Przepiera-Bedzak1, Iwona Brzosko, Jacek Fliciński, Włodzimierz Samborski, Marek Brzosko.   

Abstract

OBJECTIVE: Presentation of clinical features of the SAPHO syndrome.
MATERIALS AND METHODS: Seventeen patients (15 women and 2 men) with confirmed diagnosis of the SAPHO syndrome was presented. The culture of biopsy of pustulotic skin lesions was performed in 11 patients. ESR, C-reactive protein level and Waaler-Rose test were determined in all patients, and antinuclear antibodies and bone scintigraphy were performed in 16 patients. X-ray of the sterno-clavicular joints was performed in 15 patients.
RESULTS: The age of patients was 22-59 yr. (mean: 47.1 yr). The duration of joint symptoms was 0.1-25 yr. (mean: 4.4 years). Pustulosis was presented in 16 patients, only 1 patient had acne. All patients suffered from pain localized on the anterior chest wall. Tenderness of the peripheral joints: wrist (in 7 patients), shoulder (in 7 patients), knee (in 4 patients) was shown. In 6 patients, skin changes preceded joint symptoms, in 2 patients skin changes followed joint symptoms after 5 and 10 yr., respectively. All patients had negative the Waaler-Rose test. Active inflammatory process characterized by an increased ESR and C-reactive protein level was present in 12 patients. Abnormalities in x-ray of the sterno-clavicular joints were present in 4 patients. Characteristic alternations for the SAPHO syndrome in scintigraphic picture of the skeleton were observed in 14 patients. All patients were treated with non-steroidal anti-inflammatory drugs. In 8 patients, treatment with antibiotics, in 11 patients--with sulfasalazine, in 3 patients--with methotrexate and low doses of glucocorticosteroids, in 1 patient--with colchicines was performed.
CONCLUSIONS: Association of typical skin changes with pain of the anterior chest wall is the key for diagnosis of the SAPHO syndrome. It seems that this syndrome is more common in Poland than it has been previously estimated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18634527

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  2 in total

1.  Serum interleukin-23 protects, whereas methotrexate treatment stimulates selected components of the metabolic syndrome in patients with SAPHO syndrome.

Authors:  Hanna Przepiera-Będzak; Katarzyna Fischer; Marek Brzosko
Journal:  Arch Med Sci       Date:  2018-07-05       Impact factor: 3.318

Review 2.  SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review.

Authors:  Hanna Przepiera-Będzak; Marek Brzosko
Journal:  Postepy Dermatol Alergol       Date:  2020-07-23       Impact factor: 1.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.